Oncology Central

FLAURA trial: discover novel therapeutic strategies for lung cancer


Could you briefly introduce yourself and tell us a little about your background?

As a thoracic oncologist, I provide care for patients with lung cancer and conduct research. My research involves development of new treatment options for lung cancer. I serve as the director of Medical Oncology at the Winship Cancer Institute of Emory University (GA, USA).

Could you give us a brief overview of the FLAURA trial? 

FLAURA was conducted to compare the effectiveness of osimertinib to standard EGFR inhibitors. EGFR mutations are observed in approximately 15–35% of patients with lung adenocarcinoma, a common subtype of lung cancer. For these patients, erlotinib and gefitinib are two of the most commonly used treatments. Patients develop resistance to erlotinib and gefitinib in approximately 10 months and the drug stops working. In nearly half the cases of resistance, a new mutation termed the T790M mutation is acquired in the tumors and renders erlotinib and gefitinib ineffective.

Osimertinib belongs to a new generation of EGFR inhibitors that is very safe and inhibits the T790M mutation along with the original EGFR mutations. Osimertinib is approved for the treatment of patients that develop T790M mutation after treatment with erlotinib/gefitinib. We conducted the FLAURA study to investigate whether osimertinib could be utilized as ‘first-line therapy’ for patients with EGFR mutation (instead of erlotinib/gefitinib).

The primary endpoint of the study was to compare progression-free survival (PFS).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.